Pharma investors—gene therapy is not the golden goose you were led to believe it would be—get your money out and save the world at the same time
SOUND THE WARNING BELL NOW, FOR THE SAKE OF HUMANITY!
This is the gene therapy (genetic engineering) hype:
Investor Confidence in Gene Therapy Rallies in 2022: Are We at a Tipping Point in Genetic Medicine?
“Gene therapies offer the possibility of curative treatments across the medical spectrum: from rare, severe and otherwise untreatable genetic disorders to more common chronic metabolic conditions. Investor interest in the field seems to have rallied this year after stalling briefly in 2021 in the face of regulatory hesitancy following safety concerns and underwhelming trial results.
A flurry of recent Big Pharma acquisitions and other investments into gene therapy start-ups has caught the eye of investors on Wall Street and around the world. The FDA’s approval of the haemophilia B treatment Hemgenix on 22 November 2022 is the latest example of a gene therapy success story.”